NavigAID for Autoimmune Disease: Stratifying patients for improved therapeutic success

Protagen has developed a pipeline of NavigAID stratification arrays, based on autoantibody signatures, for a number of autoimmune diseases to help overcome issues such as patient heterogeneity.

Autoimmune diseases are highly diverse, and the level of patient heterogeneity observed makes the development of effective treatments challenging. One solution is to stratify patients based on the specific characteristics of their individual autoimmune disease, including the detection of biomarkers that are central to the disease’s pathology—autoantibodies.

Developing tools that are able to detect autoantibody signatures in patients suffering from autoimmune diseases will enable the immune-competence of a patient to be assessed, and their therapeutic responsiveness to be predicted.

The SeroTag® biomarker identification platform has allowed Protagen to do this, and to develop an array of disease-specific NavigAID stratification panels to profile individual patients’ diseases. This enables the stratification of patients into distinct disease subgroups based on their autoantibody profiles, an approach which is designed to help predict treatment response and support better patient management.

Protagen has developed a pipeline of NavigAID stratification arrays, based on autoantibody signatures, for a number of autoimmune diseases. These have been created following our close collaboration and communication with a number of key industry opinion leaders, advocacy groups and major pharmaceutical and biotech companies, and address the following key questions:

  • Can we ensure enrollment of an appropriate patient population?
  • Can we identify patients with high disease activity?
  • Can we predict disease-specific organ damage?
  • Is it possible to stratify SLE, RA, SSc and/or Sjögren’s into different subgroups and allow enrichment/prediction of responders?

Protagen has developed its NavigAID arrays to address these questions, and has been engaged by 7 of the top 10 pharmaceutical companies to support their product development. For more information on how the NavigAID tools are being used for autoimmune diseases, follow the navigation below.

NavigAID SSc is a disease stratification array designed to support pharmaceutical and biotechnology companies with their SSc drug development efforts by defining specific disease subgroups via the straightforward measurement of serum autoantibodies.

NavigAID SLE is a stratification tool that separates and defines subgroups of SLE patients in order to overcome disease heterogeneity, and support biotechnology and pharmaceutical companies with their drug development programs.

NavigAID SjS is a patient stratification tool that measures serum autoantibody levels in Sjögren’s patients, in order to help to characterize the immunological processes underlying the disease and help facilitate the development of more effective therapies.

NavigAID RA is a patient stratification tool that measures autoantibodies in serum to help group patients based on the immunological processes underlying their condition, to help advance the development of precision medicine treatments and approaches.

Get in touch

Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.

We sometimes like to share the latest industry insights and company news, would you like to be added to our database?

13 + 3 =

Copyright © 1997-2018
Protagen AGDortmund, Germany